US EditionGilead to buy Germany's Tubulis for up to $5 billion to boost cancer pipeline
- On Tuesday, Gilead Sciences announced it will acquire German biotech Tubulis in a deal valued at up to $5 billion, including a $3.15 billion upfront payment and $1.85 billion in milestone-based payments.
- Gilead Chief Executive Daniel O'Day said the acquisition is "a significant milestone" as the company expands its oncology pipeline ahead of HIV patent expirations in coming years.
- Tubulis specializes in stable antibody-drug conjugates, with lead assets TUB-040 and TUB-030 targeting platinum-resistant ovarian cancer and other solid tumors using specialized protein-linking technology.
- This acquisition follows Gilead's recent $7.8 billion deal for Arcellx and up to $2.18 billion offer for Ouro Therapeutics, marking its third major acquisition this year.
- While antibody-drug conjugates show promise, the category faces clinical risks; ADC Therapeutics' trial failures underscore challenges Gilead navigated through its $21 billion Immunomedics acquisition and Trodelvy experience.
20 Articles
20 Articles
marketbeat.com
themarketsdaily.comGilead Sciences Details Tubulis, Ouro, Arcellx Deals as Pipeline Catalyst, 2026 Updates Loom
Gilead Sciences (NASDAQ:GILD) executives on Tuesday outlined the company’s rationale for three recently announced transactions—its proposed acquisitions of Tubulis, Ouro Medicines, and Arcellx—framing the deals as additive to an already active late-stage pipeline and consistent with the company’s bu
Gilead Acquisition Spree Continues With $3 Billion Tubulis Deal - Gilead Sciences (NASDAQ:GILD)
Gilead Sciences Inc. (NASDAQ:GILD) shares are down on Tuesday as the company announced a $3.15 billion acquisition of Tubulis GmbH. The Foster City, California-based firm aims to enhance its oncology pipeline. The acquisition adds TUB-040, a promising antibody-drug conjugate (ADC) for the treatment of ovarian cancer, to Gilead’s existing oncology portfolio. Tubulis currently has two programs in clinical trials for solid tumor indications. Gilead…
US pharma firm Gilead to acquire German biotech company Tubulis to boost cancer pipeline
Tubulis' antibody-drug conjugate platforms to provide Gilead with next-generation treatments for ovarian, lung cancers, while its Munich plant planned to serve as innovation hub under American drug maker
The Munich-based cancer research company Tubulis was considered one of the great German sources of hope in the biotech industry. The start-up is now taken over by the US pharmaceutical giant Gilead.
Coverage Details
Bias Distribution
- 75% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
